IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shimazaki, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/06168

Title: Carboxamides Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray

Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2712 Facsimile: (203) 812-5492

Form PTO (Modified)	U.S. Depart of Commerce Patent and Trademark Office							Serial No.	Art Unit	ing	ing pate / 5tty Decket No.				
INFORMATION DISCLOSURE CITATION									Applicant(s) Shimazaki,	ot al					
							U.	 S P/	ATENT DOCU						
		-,						3. 1 .,				 			
		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	П	DATE F PRIATE	
	U1	4	6	7	0	5	8	4	06/02/87	Toyoshima, et al.	562/449				
	U2	4	7	1	4	7	1	3	12/22/87	Fukushima, et al.	514/563				
			<u> </u>	-		-	_	_					<u> </u>		
			-	-	+	-	-		-				+		
							<u> </u>						<u> </u>		
]	FORI	EIGN	PATENT DO	CUMENTS					
		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSI	LATION	
	F1	0	3	1	0	6	4	03	24/12/03	wo	C07C	235/34			
	F2	0	1	6	8	5	9	1	20/09/01	wo	C07C	271/22			
	F3	0	0	5	0	3	9	7	31/08/00	WO	C07D	211/86			
					<u> </u>			<u></u>							
			<u>отн</u>	ER R	EFE	REN(CES (Inclu	ding Author, 7	Fitle, Date, Pert	inent Pages	s. etc.)			
	R1	Amir	no, Y.	. et al.,		ylalani				ntestinal Absorptio			em. Pharm	ı. Bull.,	
	R2	Moh	Mohan, Raju, et al., <u>5580356</u> Journal, JMCMAR, J, Med. Chem., EN, <u>34</u> , 2402-2410, (1991). XP-002257552												
	R3	Schlizer, Martin, et al., <u>6249813</u> Journal BMECEP, Bioorg. Med. Chem.; EN, <u>8</u> , 1991-2006, (2000). XP-002257553													
	R4	Schlizer, Martin, et al., <u>6249813</u> Journal BMECEP, Bioorg. Med. Chem.; EN, <u>8</u> , 1991-2006, (2000). XP-002257554.													
	R5	Kmetic, Matej, et al., <u>6094085</u> Journal JHTCAD, J. Heterocycl Chem.; EN; <u>34</u> , 1705-1708, (1997). XP-002257555.													
	R6	Blume, H., et al., <u>5792715</u> Journal, ARZNAD, GE; Arzneim Forsch., <u>31</u> , 1731-1735, (1981). XP-002257556.													
	R7		 uzyan, 002257		et al., į	<u>58113′</u>	<u>76</u> Jou	mal, F	CJOAU; EN, Ph	narm. Chem. J., <u>26</u> .	. 579-582, (19	992).			
	R8		eson, R		t al., 1	59542	, Journ	nal, JC	SOA9, EN, J. CI	hem. Soc., 3457-34	461, (1960).				
EXAMINE	R								DATE	CONSIDERED					
*EXAMINI and not con	ER: Init	ial if ci Includ	itation (conside	ared, wi	hether (or not c	itation munica	is in conformance ation to applicant.	with MPEP 609. Dr	aw line throug	h citation if n	ot in confor	mance	